{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:55:44Z","timestamp":1789977344545,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.vaccine.2016.08.069","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T20:10:34Z","timestamp":1473106234000},"page":"4850-4856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Comparative impact of pneumococcal conjugate vaccines on pneumococcal meningitis according to underlying conditions"],"prefix":"10.1016","volume":"34","author":[{"given":"Robert","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Varon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"B\u00e9chet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bonacorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.08.069_b0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1473-3099(16)00054-2","article-title":"Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study","volume":"16","author":"Mackenzie","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0010","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1016\/j.vaccine.2012.08.012","article-title":"Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel","volume":"30","author":"Ben-Shimol","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.069_b0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/INF.0b013e318124a494","article-title":"Surveillance for invasive pneumococcal disease during 2000\u20132005 in a population of children who received 7-valent pneumococcal conjugate vaccine","volume":"26","author":"Black","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.08.069_b0020","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1016\/j.vaccine.2013.10.032","article-title":"Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway","volume":"31","author":"Steens","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.069_b0025","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa1005384","article-title":"Bacterial meningitis in the United States, 1998\u20132007","volume":"364","author":"Thigpen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.08.069_b0030","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12325-013-0051-2","article-title":"A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis","volume":"30","author":"Tin Tin Htar","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2016.08.069_b0035","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1086\/587897","article-title":"Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States","volume":"46","author":"Tsai","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0040","doi-asserted-by":"crossref","first-page":"e1001517","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2016.08.069_b0045","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ368","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children","author":"Olarte","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0050","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/infdis\/jiu213","article-title":"Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England","volume":"210","author":"Moore","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.vaccine.2014.11.011","article-title":"Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001\u20132012","volume":"33","author":"Lepoutre","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.069_b0060","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erv.12.53","article-title":"The fundamental link between pneumococcal carriage and disease","volume":"11","author":"Simell","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.08.069_b0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1473-3099(04)00938-7","article-title":"Streptococcus pneumoniae colonisation: the key to pneumococcal disease","volume":"4","author":"Bogaert","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0070","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1016\/j.vaccine.2015.08.010","article-title":"A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation","volume":"33","author":"Cohen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.069_b0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa0800836","article-title":"Effect of pneumococcal conjugate vaccine on pneumococcal meningitis","volume":"360","author":"Hsu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.08.069_b0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0b013e318275614b","article-title":"Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine","volume":"32","author":"Kaplan","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.08.069_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/cid\/civ692","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children","volume":"62","author":"Levy","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/acem.12203","article-title":"Rates of emergency department visits due to pneumonia in the United States, July 2006-June 2009","volume":"20","author":"Self","year":"2013","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.vaccine.2016.08.069_b0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1542\/peds.2014-0473","article-title":"Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine","volume":"134","author":"Iroh Tam","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.08.069_b0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ijcp.12234","article-title":"The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe","volume":"68","author":"Rose","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.vaccine.2016.08.069_b0105","unstructured":"Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62:521\u20134."},{"key":"10.1016\/j.vaccine.2016.08.069_b0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3201\/eid1901.120741","article-title":"Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales","volume":"19","author":"Ladhani","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1542\/peds.2014-2426","article-title":"Members of the massachusetts department of public H. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease","volume":"135","author":"Yildirim","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.08.069_b0120","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0; 2016 <http:\/\/www.eucast.org\/. 2016>."},{"key":"10.1016\/j.vaccine.2016.08.069_b0125","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.arcped.2013.05.016","article-title":"Annual trends (2008\u20132011) in early childhood vaccination coverage for the French population: the Vaccinoscopie((R)) study","volume":"20","author":"Martinot","year":"2013","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.vaccine.2016.08.069_b0130","unstructured":"French national center for disease control. <http:\/\/www.invs.sante.fr\/Dossiers-thematiques\/Maladies-infectieuses\/Maladies-a-prevention-vaccinale\/Infections-invasives-d-origine-bacterienne-Reseau-EPIBAC\/Bulletin-du-reseau-de-surveillance-des-infections-invasives-bacteriennes>; 2016."},{"key":"10.1016\/j.vaccine.2016.08.069_b0135","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/cid\/cit791","article-title":"Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5\u201315 years in England and Wales","volume":"58","author":"Ladhani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0140","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1016\/j.vaccine.2015.10.015","article-title":"Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children","volume":"33","author":"Varon","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.069_b0145","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1183\/09031936.00080814","article-title":"Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types","volume":"44","author":"Browall","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2016.08.069_b0150","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/cid\/cit792","article-title":"The challenge of preventing invasive pneumococcal disease in children with comorbid illnesses","volume":"58","author":"Pelton","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0155","unstructured":"French vaccinar calendar. <http:\/\/social-sante.gouv.fr\/IMG\/pdf\/Calendrier_vaccinal_2015.pdf>; 2015."},{"key":"10.1016\/j.vaccine.2016.08.069_b0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1017\/S0950268807008436","article-title":"Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999\u20132005","volume":"136","author":"Pebody","year":"2008","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.08.069_b0165","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2015.07.009","article-title":"Pneumococcal disease in the era of pneumococcal conjugate vaccine","volume":"29","author":"Yildirim","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.vaccine.2016.08.069_b0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jinf.2012.02.017","article-title":"The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England","volume":"65","author":"van Hoek","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.08.069_b0175","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/cid\/ciu274","article-title":"Invasive pneumococcal disease in children can reveal a primary immunodeficiency","volume":"59","author":"Gaschignard","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0180","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1086\/374624","article-title":"Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential","volume":"187","author":"Brueggemann","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.069_b0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/IAI.73.1.431-435.2005","article-title":"Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland","volume":"73","author":"Hanage","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.069_b0190","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/JCM.01763-10","article-title":"Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype","volume":"49","author":"Sa-Leao","year":"2011","journal-title":"J Clin Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T07:16:18Z","timestamp":1556349378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16307654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":38,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0264410X16307654"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative impact of pneumococcal conjugate vaccines on pneumococcal meningitis according to underlying conditions","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}